Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2020-06-13
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies stereotactic radiosurgery and metformin hydrochloride in
treating patients with pancreatic cancer that may be removed (borderline-resectable) or not
removed by surgery. Stereotactic radiosurgery may be able to send x-rays directly to the
tumor and cause less damage to normal tissue. Metformin hydrochloride, used for diabetes, may
also kill cancer cells as demonstrated in laboratory studies. Giving stereotactic
radiosurgery with metformin hydrochloride may kill more tumor cells.